Biogen share price soars as US accepts drug for Alzheimer’s
Biogen’s share price leapt after its controversial Alzheimer’s disease therapy was approved by US
regulators, a landmark decision that stands to dramatically change treatment for the debilitating brain
condition, reported Bloomberg News (9 June 2021) The stock gained as much as 64% shortly after the news of the clearance. The Food and Drug Administration (FDA) granted the antibody therapy accelerated approval.
The approval is the first clearance of an Alzheimer’s therapy by the FDA since 2003, and one of the agency’s most consequential decisions in years.